We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Cancels Sugammadex Meeting, Merck Cites Trial Site Inspection
FDA Cancels Sugammadex Meeting, Merck Cites Trial Site Inspection
July 19, 2013
The FDA abruptly cancelled the July 18 meeting of its Anesthetic and Analgesic Drug Products Advisory Committee that was originally scheduled to discuss Merck’s NDA for sugammadex sodium injection.